Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Tonix Pharmaceuticals Holding Corp.

  • Seth Lederman, Tonix Pharmaceuticals

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix is developing Tonmya, which is in Phase 3 development and has been granted Breakthrough Therapy designation, as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer’s disease under a separate IND to support a Phase 2, potential pivotal, efficacy study and has been designated a Fast Track development program by the FDA. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but by a unique mechanism and designed for daytime dosing. Tonix’s lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.

  • Date:Monday, February 11
  • Time:2:30 PM - 2:45 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23295
  • Goal for Presentation:General Awareness of Tonix's current pipeline and upcoming milestones
  • Company Website:www.tonixpharma.com
  • Company HQ City:new york
  • Company HQ State:New York
  • Company HQ Country:United States
  • Market Cap:$8.0M
  • Ticker:TNXP
  • Exchange:NASDAQ
  • CEO/Top Company Official:Seth Lederman
  • Year Founded:2007
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:Tonmya
  • Development Phase of Primary Product:Phase III
Speakers
Seth Lederman
Tonix Pharmaceuticals
Back